BCL2 and systemic lupus erythematosus: B-cell lymphoma 2 (Bcl-2) is critical for pDC survival and IFN-I production in lupus mice or patients with SLE, and the use of the selective Bcl-2 inhibitor venetoclax (ABT-199) significantly reduces auto-reactive B cell and total lymphocyte counts and alleviates disease symptoms in female patients [229, 230].